Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849562 | 0.88 | DYRK1A (0.38) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4855991 | 0.88 | DYRK1A (0.51) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4847918 | 0.86 | DYRK1A (0.52) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4855278 | 0.77 | CYP11B1 (0.42) | DYRK1ANFATC1GSK3BKCNH2CYP11B1 | |
| SCHEMBL4849658 | 0.77 | DYRK1A (0.67) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4858180 | 0.76 | DYRK1A (0.46) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4855827 | 0.75 | DYRK1A (0.47) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4856748 | 0.75 | DYRK1A (0.48) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4857053 | 0.74 | DYRK1A (0.43) | DYRK1ANFATC1GSK3BKCNH2KDM4C | |
| SCHEMBL4856807 | 0.74 | CNR1 (0.44) | DYRK1ANFATC1GSK3BKCNH2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | DYRK1A 1117/4885NFATC1 1618/4885GSK3B 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.